

New Zealand Hospital Pharmacists'
Association (Inc)

Te Kāhui Whakarite Rongoā Hōhipera o Aotearoa



Annual Report

2009 - 2010

**NEW ZEALAND HOSPITAL PHARMACISTS'
ASSOCIATION**

Te Kāhui Whakarite Rongoā Hōhipera o Aotearoa

ANNUAL REPORT 2009/2010

PRESIDENT

Billy Allan

IMMEDIATE PAST PRESIDENT

(vacant this year)

EXECUTIVE MEMBERS

Simon Jamieson

Nirasha Parsotam

Lorraine Welman

Dianne Wright

OFFICIAL ARCHIVIST

Euan Galloway

SPECIAL INTERST GROUP CONVENORS

Drug Information and Clinical Pharmacy

Jocelyn Livesey

Management

Melissa Witbrock

Compounding, Nutrition and Oncology

Paula Ferguson

Mental Health

Corina Young

Pharmacy Technician

Dianne Gulliver



President's Annual Report 2010

Vision: Supporting innovation in the practice of pharmacy and promoting effective medicines management

I have great pleasure in presenting the 58th Annual Report of the New Zealand Hospital Pharmacists' Association (NZHPA) for the 2009/10 year.

This year Stephen Duffull retired from the Executive. Stephen was replaced by Simon Jamieson. Otherwise the Executive was unchanged with Billy Allan as President, Lorraine Welman (Treasurer), Dianne Wright (Secretary), Nirasha Parsotam (SIG Co-ordinator). Simon took on the role of Newsletter Editor. Euan Galloway remained as our Archivist.

I would like to formally thank all the NZHPA Executive for giving considerable time, effort and talent to ensure that the Association's affairs are managed appropriately and effectively. The Executive does so willingly and on a voluntary basis.

Executive Activities

The Executive met as follows:

4 December 2009	Wellington
8 April 2010	Wellington
15 July 2010	Wellington

and we are due to meet before Conference on the 2nd / 3rd September. Between face-to-face meetings considerable business is dealt with by email.

Examples of specific activities that the Executive have been working on include:

1. Responded to the following consultations and discussion documents:
 - a. Review of Access to High-Cost, Highly-Specialised Medicines in New Zealand, MoH (McCormack et al)
 - b. Proposal to amend claiming for Cost Brand Source prescriptions, PHARMAC
 - c. Consultation for Possible Expansion of PHARMAC's role', PHARMAC
 - d. Review of School of Pharmacy Postgraduate Programmes, SoP UoA
 - e. Consultation on Proposed Amendments to Regulations under the Medicines Act 1981, MoH
 - f. Consultation on Legislative barriers to workforce innovation, the Office of Hon Tony Ryall
 - g. National Health IT Plan Draft for Discussion, National Health IT Board
2. Participated in meetings and reviews:
 - a. PSNZ hosted 'Actioning Medicines New Zealand: Advancing the Optimal Use of Medicines in the Primary Healthcare Sector through better use of the pharmacist

- workforce' workshop. This workshop was hosted by Hon Peter Dunne, Associate Minister of Health.
- b. Collaborative Pharmacy Practice – Pharmacist Prescribers workshop, PCNZ, 6th Nov 2009
 - c. Presented at and participated in the PSNZ sponsored Workforce Training Education forum for Sector Leaders, 9th April 2010
 - d. MoH sponsored, Standards NZ development of Pharmacy Service Standards, published March 2010 (8134.7:2010 Health & Disability Services Standards – Pharmacy Service Standard)
 - e. The Review and Development of New Pharmacy Service Standards, published (Health and Disability Services Pharmacy Services Standard NZS 8134.7, Standards New Zealand, April 2010)
 - f. The Review of Pharmacy Recalls, MoH
3. Reviewed and updated the NZHPA SIG Handbook
 4. Commenced a review of the Association's Strategy 2011 - 2015

Liaison with Associated Bodies

The NZHPA has been represented on the following committees:

- | | |
|--|------------------|
| 1. Heads of Schools and Professional Organisation of Pharmacy (HOSPOP). This twice yearly meeting is to replace the separate Schools of Pharmacy Advisory Committee / Boards of Studies meetings | Kirsten Simonsen |
| 2. Board of Studies – SoP, UoO | Kirsten Simonsen |
| 3. Board of Studies – SoP, UoA | Sian Dawson |
| 4. Accident Compensation Corporation Pharmacy Liaison Group | Chris Jay |
| 5. Pharmacy Industry Training Organisation (PITO) | Sanjoy Nand |
| 6. Pharmacy Reference Group for the Implementation of the Strategy for Maori Health (PRISM) | Billy Allan |
| 7. NZ Pharmacy Education & Research Foundation (NZPERF) | Lorraine Welman |
| 8. Standards New Zealand; Development of the Pharmacy Service Standards | Billy Allan |
| 9. Safe Medication Management Programme (SMMP) | Billy Allan |
| 10. New Zealand Universal List of Medicines (NZULM) | Billy Allan |

The Executive is most grateful for Members who offer to represent the Association at these various national forums.

Awards

The Association continues to maintain a broad portfolio of awards for the benefit of members:

Award	Recipient 2009/10
1. Ebewe Award – Joint Award	Laura Clunie and Ruth Tramschek
2. Sanofi-Aventis Award	Charlotte Jones
3. Baxter Award	Jan Goddard - Unfortunately Jan was unable to take up her award. It was therefore re-advertised.
4. Baxter Award – re-advertised	Louise McDermott
5. NZHPA Education Fund	Paula Ferguson
6. NZHPA Education Fund	Victoria Kershaw (withdrawn)
7. NZHPA Education Fund	Hesham Al-Sallami
8. NZHPA Education Fund	Sanja Mirkov

The pharmaceutical company awards would not be possible without the continuing support from their sponsors, in particular Baxter Healthcare, Ebewe, Sanofi-Aventis and GlaxoSmithKline. The NZHPA is most appreciative of their support and encouragement of our members. Unfortunately, we are unable to offer the Baxter Development Fund this year as Baxter Healthcare has withdrawn its sponsorship for 2010 – a sign of the international economic downturn.

It is great to see the recipients of the NZHPA awards sharing their experiences though published articles and presentation at Conference and SIG meetings. Now that The Pharmaceutical Journal for New Zealand (PJNZ) is no longer being published award recipients' reports are published on the NZHPA website (members' only section).

The NZHPA also offers a range of awards to undergraduates and postgraduates through the Schools of Pharmacy. Last year's recipients were:

Award	Recipient 2009/10
1. NZHPA Award for Aseptic Dispensing (UoA)	Zhichao (Harry) Jin
2. NZHPA Award for Integrated Pharmacy Studies (UoA)	Nicola Anne Williams
3. NZHPA Award in the Postgraduate Diploma in Pharmacy Practice (UoA)	Not awarded
4. NZHPA Syd Little Memorial Prize (UoO), Highest standard of achievement in Drug Delivery Systems and Drug Disposition and Pharmacokinetics. Top average of PHCY342 & 343	Su Sern Samuel Pau
5. Pharmacy Prize in Clinical Pharmacy (UoO), for the best achievement in the 3 Quality Use of Medicines papers PHCY345, PHCY471 and PHCY473	Timothy Vincent

Other activities

1. **NZHPA Workforce Development Working Group** (Kim Brackley, Chris Jay, Melissa Witbrock and Sanja Mirkov). A Health Services Researcher has been appointed to develop a proposal over the next 4-6 months, for a national career structure for hospital pharmacy staff. The group's purpose is to develop a proposal for the NZHPA Executive (and therefore membership) as to the feasibility of developing a nationally agreed career or pay structure for

hospital pharmacy staff. This is a significant piece of work and expense for the Association.

2. **Standards for Clinical Pharmacy** The formal review and development of the Association's Clinical Pharmacy Guidelines 2007 continues.

The work includes:

- a) A general review to ensure things are current e.g. could add a section on medicines reconciliation (MR) using the SMM Programme material as a basis;
- b) To include the cases / scenarios that Chris Jay has obtained from the UK;
- c) To include a section on resources and staffing levels (sections 7 and 8 of the SHPA's Standards of Practice for Clinical Pharmacy, 2005); and
- d) Adapt the existing SHPA document appendices (A-L) to the NZ environment, cross-referencing to these in the body of the guidelines.

Notes on Injectable Drugs (NoIDs)

Lucy Broughton, co-ordinating editor, has been busy developing the 6th edition of NoIDs. It is anticipated that this will be published and printed before Christmas 2010.

NoIDs is a major source of income for NZHPA. The Association is indebted to Lucy and her band of editors for updating and preparing the monographs for this nationally respected publication.

Website

Dave Woods continues as our Webmaster maintaining the website. The Members' Only section is proving to be very valuable for communicating with members. We are utilising the website to a greater extent, with responses to consultations and minutes of Executive meetings (once ratified; on the Members' Only section) being accessible through the site.

Thank you Dave for your continuing management of the website.

Conferences and Seminars

The flagship event for the Association is the annual conference. The 2009 conference in Nelson (All That's Good in Life) was a terrific success. My thanks to Simon Jamieson and Annie Egan for their time, effort and hard work in pulling off an excellent conference that should have met all delegates' expectations educationally, collegially and at a social level.

Throughout the year the following Special Interest Group (SIG) meetings were held:

1. A combined DICP / CNO, 1 - 2 May, in Wellington (Chloe Campbell and Anita Frew)
2. Technician SIG, Continuing Education Day, 7 November, in Christchurch (Bronwyn Baiteary and Ros Hadler)
3. Technician SIG, Risky Business, 29 May, in Hastings (Kelly Flight and Brenda Edwards)
4. Pharmacists in Mental Health, Past, Present and Future, 7 - 8 August, in Auckland (Nikki Holmes)

5. Management SIG, 29 July, in Auckland (Melissa Witbrock)

Yet another series of successful meetings. These meetings are the backbone of the Association. So 'Special Thanks' to all the SIG, conference and meeting convenors for their dedication in providing such diverse meetings to such a high standard.

Membership

Membership numbers for 2009/10 have increased slightly over past years:

Member category	2002/03	2003/04	2004/05	2005/06	2006/07	2007/08	2008/09	2009/10
Ordinary	169	149	72	163	199	214	211	227
Associate	17	16	11	36	45	29	30	38
Corporate	3	7	3	5	4	4	3	3
Total¹	189	172	86	204	248	247	244	268

1 Excludes Life and Fellow members

The last increase in fees was at the beginning of the 2006/07 financial year.

Strategic Priorities 2005-10

It is over five years since the Association developed its Strategy 2005 - 2010, with a review in February 2008 and April 2009. The Executive has now commenced a full review of the Association's strategic priorities for the next five years, 2011 - 2015. We are reviewing:

- What is our purpose? Why does NZHPA exist?
- Where is the Association now?
- Where do we want to get?
- How will we get there?
- Does the Association have the capacity to get to where it wants to go?

This process was facilitated by Joe Asghar (ex NZHPA Executive member) and should be completed by early 2011.

The Association's existing Vision is:

Supporting innovation in the practice of pharmacy and promoting effective medicines management

The Association's six broad strategic goals are:

1. Align with sector key partners to increase the contribution from and the visibility of, NZHPA.
2. To ensure that the NZHPA's philosophy and strategy encompass the Māori Health Strategy for the Pharmacy Profession, recognising Māori well being as a priority for the Association.
3. Use available expertise and knowledge from the membership to build links with colleges/universities and PSNZ on educational activities.
4. Develop a plan to address issues of recruitment, retention and continuing professional

development, supporting the development of pharmacists' roles across all sectors (primary care, secondary care and PHOs).

5. Establish a Special Interest Group with the ability to respond to policy consultations on behalf of NZHPA.
6. Capture the passion and enthusiasm of the membership to increase organisational visibility.

We have made significant steps to realise these goals, but have still some way to go to achieve full realisation.

Are these goals still relevant? Is this the appropriate direction for the NZ Hospital Pharmacists' Association? What direction would you like the Association to take? Please share your thoughts on where NZHPA is going with me or a member of the Executive.

The Association remains strong and has gained recognition at a national level; but we still have some way to go. As a voluntary membership organisation we are largely reliant on the time and goodwill of the membership. I would like to acknowledge and thank all the SIG convenors, meeting and conference organisers, editors, webmaster, members who represent the Association at the various forums, our archivist and the Executive for freely giving their time and talents and making a tremendous contribution to the Association. However, we must be cautious that the Association does not become reliant on the efforts of a few.

I wish the Association and the new Executive well for the coming years.

William (Billy) Allan
President
July 2010

**NEW ZEALAND HOSPITAL
PHARMACISTS' ASSOCIATION
INCORPORATED**



Financial Statements

For the year ended 31 May 2010

Statement of
Financial Performance

For the year ended 31 May 2010

	Note	2010 (\$)	2009 (\$)
Operating revenue			
Membership subscriptions		23,856	22,307
Members' activities	1	55,658	52,009
Conference	2	144,661	192,161
Grants and awards	3	10,500	4,000
Interest		7,336	13,211
Total operating revenue		242,011	283,688
Operating expenditure			
Members' activities	1	38,033	37,862
Conference	2	111,800	173,593
Grants and awards	3	23,055	15,134
Administration	4	52,536	46,412
Total operating expenditure		225,424	273,001
Net operating surplus before taxation		16,587	10,687
Tax credit/(expense)		4,704	(3,416)
Net operating surplus for the year		21,291	7,271

Statement of
Movements In Equity

For the year ended 31 May 2010

	2010 (\$)	2009 (\$)
Net operating surplus for the year	21,291	7,271
Total recognised revenues and expenses	21,291	7,271
Equity at the beginning of the year	179,132	171,861
Equity at the end of the year	200,423	179,132

The Statement of Accounting Policies and Notes to the Financial Statements on pages 3 to 8 form part of the financial statements

Statement of
Financial Position

As at 31 May 2010

	Note	2010 (\$)	2009 (\$)
Current assets			
Cash and bank balances		22,649	15,280
Receivables and accruals	5	50,634	34,694
Inventory		2,827	4,937
Investments	6	170,000	180,000
Total current assets		246,110	234,911
Non-current assets			
Website		1,364	2,999
Total non-current assets		1,364	2,999
Total assets		247,474	237,910
Current liabilities			
Payables and accruals	7	47,051	58,778
Total current liabilities		47,051	58,778
Net assets		200,423	179,132
Equity			
Retained earnings	8	67,163	59,431
Special interest groups	9	85,557	67,729
Special funds	10	47,703	51,972
Total equity		200,423	179,132

On behalf of the Executive Council



W Allan
 President
 27 July 2010



L Welman
 Treasurer
 27 July 2010

The Statement of Accounting Policies and Notes to the Financial Statements on pages 3 to 8 form part of the financial statements

Statement of

■ Accounting Policies

For the year ended 31 May 2010

Basis of preparation

The New Zealand Hospital Pharmacists' Association Incorporated (the Association) is incorporated under the Incorporated Societies Act 1908 (the Act). These financial statements are prepared in accordance with the Act and generally accepted accounting practice.

Measurement base

These financial statements have been prepared on a going concern basis in accordance with historical cost concepts.

Specific Accounting Policies

The following specific accounting policies that materially affect the measurement of the financial performance and financial position have been applied.

Revenue and expenditure recognition

All revenue is recognised when earned on an accruals basis, except for donations which are recognised on a cash basis when payment is received. All expenditure is recognised when billed or an obligation arises on an accruals basis, except for donated services.

Donated services

The work of the Association is dependent on the voluntary services of members and the Pharmaceutical Society of New Zealand (Incorporated). Due to the difficulty in determining the value of the donated services with sufficient reliability, donated services are not recognised in the Statement of Financial Performance.

Taxation

Income tax expense is charged to the Statement of Financial Performance based on the estimated income tax payable in the current year, adjusted for any differences between the estimated and actual income tax payable in prior years.

Investments

Investments are stated at the lower of cost or net realisable value on a trade date basis. Debt securities are those securities where there is both the positive intent and ability to hold to maturity.

Equity

Equity is the member's interest in the Association and is measured as the difference between total assets and total liabilities. Equity is disaggregated into components to enable clearer identification of the specified uses. The components of equity are special funds and special interest groups.

Differential reporting

The Association is a qualifying entity by virtue of the fact that it has no public accountability and is small as defined by the Framework for Differential Reporting issued by the New Zealand Institute of Chartered Accountants. All available differential reporting exemptions allowed have been applied.

Comparatives

To ensure consistency with the current year, the comparative figures have been reclassified where appropriate.

Changes in accounting policies

There have been no material changes in accounting policies during the year.

Notes to the
Financial Statements

For the year ended 31 May 2010

	Income (\$)	Expenditure (\$)	Net result (\$)
1 Members' activities			
Special interest groups	42,858	25,030	17,828
Notes on injectable drugs	12,800	9,149	3,651
Costs of other conferences	-	3,854	(3,854)
Total members' activities 2010	55,658	38,033	17,625

Special interest groups	37,500	23,036	14,464
Notes on injectable drugs	14,509	8,581	5,928
Costs of other conferences	-	6,245	(6,245)
Total members' activities 2009	52,009	37,862	14,147

2 Conference			
Total conference 2010	144,661	111,800	32,861

Total conference 2009	192,161	173,593	18,568
-----------------------	---------	---------	--------

3 Grants and awards			
Ebewe Award	7,500	5,594	1,906
Sanofi-Aventis Award	3,000	2,000	1,000
Education assistance grants	-	14,511	(14,511)
Student prizes	-	950	(950)
Total grants and awards 2010	10,500	23,055	(12,555)

Baxter Award	-	3,000	(3,000)
Ebewe Award	2,500	2,500	-
GlaxoSmithKline Award	1,500	1,500	-
Education assistance grants	-	6,734	(6,734)
Student prizes	-	1,400	(1,400)
Total grants and awards 2009	4,000	15,134	(11,134)

Notes to the
Financial Statements - continued
For the year ended 31 May 2010

	2010 (\$)	2009 (\$)
4 Administration		
Accounting and secretarial services	20,961	19,055
Depreciation	1,636	409
Executive expenses	4,743	8,353
Fees paid to the auditors (includes consultancy)	10,910	11,704
Information technology	4,637	3,915
Insurance	1,542	1,496
Other working groups	4,364	-
Printing and stationery	3,505	1,030
Sundry expenses	238	450
Total administration	52,536	46,412

5 Receivables and accruals		
Trade receivables	4,578	7,598
Tax refund	324	-
Accrued income	-	1,736
Prepayments	45,732	25,360
Total receivables and accruals	50,634	34,694

6 Investments		
Term deposits	170,000	180,000
Total investments	170,000	180,000

The Association has one 180 day term deposit maturing June 2010. Interest at the rate of 4.40% is due on maturity. The deposit is held with the ANZ National Bank Limited.

7 Payables and accruals		
Trade creditors	7,402	6,615
Sundry payables	7,300	10,198
Total payables	14,702	16,813
Income in advance	32,349	26,761
Provision for tax	-	15,204
Total payables and accruals	47,051	58,778

8 Retained earnings		
Retained earnings at the beginning of the year	59,431	70,101
Net surplus for the year	21,291	7,271
Transfer (to)/from special interest groups	(17,828)	(14,464)
Transfer from/(to) special funds	4,269	(3,477)
Total retained earnings	67,163	59,431

Notes to the

■ Financial Statements - continued

For the year ended 31 May 2010

9 Special interest groups	Drug Info	Management	Oncology	Mental Health	Technicians	Total Funds
	(\$)	(\$)	(\$)	(\$)	(\$)	(\$)
Opening balance	15,559	3,708	12,032	34,732	1,698	67,729
Income	4,840	187	4,387	28,854	4,590	42,858
Expenses	1,977	123	1,479	19,027	2,424	25,030
Net result for the year	2,863	64	2,908	9,827	2,166	17,828
Closing balance 2010	18,422	3,772	14,940	44,559	3,864	85,557
Opening balance	13,927	3,486	11,044	24,166	642	53,265
Income	3,283	222	3,541	26,109	4,345	37,500
Expenses	1,651	-	2,553	15,543	3,289	23,036
Net result for the year	1,632	222	988	10,566	1,056	14,464
Closing balance 2009	15,559	3,708	12,032	34,732	1,698	67,729

The Association has established special interest groups (SIGs) in the following areas of pharmacy practice:

- Drug Information and Clinical Pharmacy
- Management
- Compounding, Nutrition and Oncology
- Pharmacists in Mental Health
- Pharmacy Technicians

The aim of each SIG is to promote and provide continuing education, interaction and peer support between members of that SIG. Each group is encouraged to run an annual seminar. Funds derived from the seminar and membership fees are attributed to that SIG to further promote other activities, such as developing national guidelines and standards of practice.

Notes to the

■ Financial Statements - continued

For the year ended 31 May 2010

10 Special funds	Baxter Fund	Ebewe Award	Glaxo Smith Kline Award	Sanofi-Aventis Award	Education Fund	Clinical School	Research School	Total Funds
	(\$)	(\$)	(\$)	(\$)	(\$)	(\$)	(\$)	(\$)
Opening balance	(3,000)	-	-	-	52,020	2,999	(47)	51,972
Income	-	7,500	-	3,000	-	-	-	10,500
Interest	-	-	-	-	7,336	-	-	7,336
Expenditure	-	(5,594)	-	(2,000)	(14,511)	-	-	(22,105)
Net result for the year	-	1,906	-	1,000	(7,175)	-	-	(4,269)
Closing balance 2010	(3,000)	1,906	-	1,000	44,845	2,999	(47)	47,703
Opening balance	-	-	-	-	45,543	2,999	(47)	48,495
Income	-	2,500	1,500	-	-	-	-	4,000
Interest	-	-	-	-	13,211	-	-	13,211
Expenditure	(3,000)	(2,500)	(1,500)	-	(6,734)	-	-	(13,734)
Net result for the year	(3,000)	-	-	-	6,477	-	-	3,477
Closing balance 2009	(3,000)	-	-	-	52,020	2,999	(47)	51,972

Notes to the
■ **Financial Statements - continued**
For the year ended 31 May 2010

10 Special funds – continued

Baxter Development Fund

This fund is used to enable hospital pharmacists to further their knowledge in the pharmacy profession, either clinical, research, or management based, and may include assistance to attend conferences.

Ebewe Pharma Oncology Pharmacy Grant

The Ebewe Award offers support for a wide range of research and professional development activities in oncology pharmacy, or oncology pharmacy management.

GlaxoSmithKline Merit Award

This in-service award is presented to a member of the Association who in the opinion of fellow members and on endorsement by the Association's Executive is "a member who has provided outstanding service to the Association and New Zealand pharmacy".

Sanofi-Aventis Pharmacy Grant

This grant is designed to offer support for a wide range of research and professional development activities in oncology and cardiovascular pharmacy.

Education Fund

The Association administers this fund, which is used to assist members to attend courses, attend conferences to present papers, or to undertake special projects.

Clinical School

This is a biennial clinical seminar/workshop for pharmacists wishing to update their clinical skills.

Research School

The Research School is a biennial event for pharmacists wanting to learn more about research in the pharmacy profession.

Notes to the
■ **Financial Statements - continued**
For the year ended 31 May 2010

11 Commitments

There are no commitments as at balance date (2009: nil).

12 Contingencies

There are no contingencies as at balance date (2009: nil).

13 Events subsequent to balance date

In the last month of the Association's financial year the Government announced that the company tax rate will reduce from 30% to 28% effective for the 2011 tax year. The financial effects of the change in tax rate have not been brought to account in the financial statements for the year ended 31 May 2010. Had the financial effect of the change in tax rate been recognised, the financial statements would not have materially differed.

There have been no other events subsequent to balance date that would materially affect these accounts.

14 Adoption of International Financial Reporting Standards

In December 2005 the New Zealand Accounting Standards Review Board ("ASRB") announced that New Zealand International Financial Reporting Standards ("NZIFRS") would apply to all New Zealand entities for the periods commencing on or after 1 January 2007.

Since this announcement, there has been some debate on the applicability of NZIFRS to small and not-for-profit entities. On 14 September 2007 the ASRB announced that the mandatory adoption of NZIFRS by some entities is to be delayed until a review is undertaken. The entities affected are those that are not required to prepare financial statements under the Financial Reporting Act 1993, are not publicly accountable, and are small as defined by the Framework for Differential Reporting issued by the New Zealand Institute of Chartered Accountants. Until the completion of the review, these entities may continue to adopt existing financial reporting standards. As the Association meets these requirements, it has elected to adopt the existing standards.



Audit report

To the members of New Zealand Hospital Pharmacists' Association Incorporated

We have audited the financial statements on pages 1 to 9. The financial statements provide information about the past financial performance of the Association and its financial position as at 31 May 2010. This information is stated in accordance with the accounting policies set out on page 3.

Executive's Responsibilities

The Executive are responsible for the preparation of financial statements which give a true and fair view of the financial position of the Association as at 31 May 2010 and the results of its operations for the year ended on that date.

Auditors' responsibilities

It is our responsibility to express an independent opinion on the financial statements presented by the Executive and report our opinion to you.

Basis of opinion

An audit includes examining, on a test basis, evidence relevant to the amounts and disclosures in the financial statements. It also includes assessing:

- the significant estimates and judgements made by the Executive in the preparation of the financial statements;
- whether the accounting policies are appropriate to the Association's circumstances, consistently applied and adequately disclosed.

We conducted our audit in accordance with New Zealand Auditing Standards. We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to obtain reasonable assurance that the financial statements are free from material misstatements, whether caused by fraud or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

Our firm has also provided taxation services to the Association. This matter has not impaired our independence as auditors of the Association. The firm has no other relationship with, or interest in, the Association.



Unqualified opinion

We have obtained all the information and explanations we have required.

In our opinion the financial statements on pages 1 to 9:

- comply with New Zealand generally accepted accounting practice;
- give a true and fair view of the financial position of the Association as at 31 May 2010 and the results of its operations for the year ended on that date.

Our audit was completed on 27 July 2010 and our unqualified opinion is expressed as at that date.

KPMG

Wellington



Pharmacists in Mental Health SIG Annual Report 2010

Introduction

The SIG seminar is due to be held on 7 - 8 August 2010 in Takapuna, Auckland. The keynote speaker is Professor David Nutt, an internationally renowned psychopharmacologist from the UK. Presenters will include a number of local psychiatrists and SIG members.

The SIG continues to be active in responding to several proposals and consultation documents. Most recently, the SIG submitted feedback to the Pharmacy Council of New Zealand proposal on Pharmacist Prescriber Scope of Practice. Dr Amanda Wheeler has been a part of the Trans-Tasman Pharmacist Prescriber Group since last January and will be attending another workshop in October 2010. She plans to present a student project with the qualitative work on collaborative prescribing in mental health and to further discuss a discharge-prescribing pilot. Following her last workshop in Australia, Dr Wheeler and colleagues wrote a letter about pharmacist prescribing published in the Journal of Primary Healthcare (Wheeler A, Hale A, Jensen M et al. Pharmacist prescribers (letter). Journal of Primary Health Care, 2010, 2(1): 72-73).

Achievements against annual plan

- The annual Pharmacists in Mental Health SIG seminar will shortly be held in Takapuna, Auckland and we are currently working to the original budget.
- We have had two successful applicants for the Mental Health Study Grant:
 - Nick Leach for her Masters degree exploring the potential role of pharmacist prescribing in the field of opioid substitution therapy from Auckland University
 - Guna Kanniah for his Postgraduate Certificate in Psychiatric Therapeutics by distance learning from Aston University, UK
- The SIG has formed closer links with the College of Mental Health Pharmacy (formerly the UK Psychiatric Pharmacy Group). A brief summary is included in the three monthly CMHP bulletin.
- The SIG has submitted responses to several proposals from Pharmac, Medsafe and the recent Pharmacy Council of New Zealand consultation on Pharmacist Prescriber Scope of Practice.
- The Yahoo chat group continues to be a useful means of communicating with colleagues about clinical and supply issues. We have had new members join from Australia who do not have such an established email network as we do in New Zealand.

Income and Expenditure

The main expenditure is the SIG seminar – details of our exact financial position will be collated after the seminar has occurred. The current financial position of the SIG remains positive. This is mainly due to sponsorship by pharmaceutical manufacturers so it needs to be borne in mind that the current financial climate may well affect this in the future. Two educational grants have been awarded (total of \$7,822 to be claimed). The SIG is supporting Dr Amanda Wheeler to attend the Trans-Tasman Pharmacist Prescriber Group meeting in Melbourne in October 2010.

Officers and Members

Nominations will take place at the AGM at the annual seminar in August 2010. The Convenor will inform the Executive shortly after the SIG seminar. Current officers are:

Convenor:	Corina Young
Deputy Convenor:	Vacant
Treasurer:	Nikki Holmes
Secretary:	Nicola Rowbottom

Total number of SIG members = 41 (as at November 2009)

Attendance at meetings

Sanofi-Aventis continue to support the North Island mental health pharmacists group this year. Four meetings have been planned for 2010 and continue to be well attended. Ongoing support for 2011 has yet to be confirmed and it is possible that it may not continue given the current financial constraints.

Corina Young
Pharmacists in Mental Health SIG Convenor
July 2010



Drug Information and Clinical Pharmacy SIG Annual Report 2010

Introduction

This year DICP SIG has made some progress in its aim to help co-ordinate and standardise the training and practice of clinical pharmacy and medicines information in New Zealand hospitals. There is an increasing willingness among members to share resources in order to help improve training and standards and we hope this will continue.

Achievements against annual plan

Several of last year's objectives remain in this year's annual plan but progress has been made on these:

Sharing of some electronic resources e.g. Micromedex to broaden access and manage costs.

- Discussion has taken place with HCN who provide Micromedex and this is ongoing. They have provided a quote for a National Consortia that now needs to be agreed by the Pharmacy Managers.
- Contact has been made with Clinical Pharmacology, another provider of an on-line comprehensive medicines database and this database is currently being trialled in several hospitals. However, some obvious gaps have been identified in terms of coverage of New Zealand drugs.

Development of Interventions database that can be used by all hospitals.

- Rob Ticehurst has further refined this database based on feedback from those hospitals trialling it. An EPIFANY working group has been created and has come up with a final proposal for database requirements. A group of software engineering students from an Australian University are currently building a web-based version of the database in conjunction with iSOFT.

Complete the review and development of Clinical Pharmacy Standards of Practice.

- Work was started on this by Annie Egan and others. Billy Allan and Di Wright have undertaken to look at finishing the adaptation of the appendices to be incorporated into the guidelines.

Promote the development and training of specialist pharmacists by identifying mentors, discussions with Pharmacy Schools, etc

- A positive response was obtained from pharmacists who would be interested in mentoring or being mentored. Some work has now been done on how to progress this and it is anticipated this will be ongoing in the next year.

Extend the use of Mi.net to more hospitals for recording MI questions.

- Three further MI centres are now using Mi.net and several smaller hospitals have shown interest.

Continue to develop and improve MI Training Manual.

- Pam undertook a survey of pharmacists to seek opinions on the usefulness of the manual and to seek ideas for improvement. As a result the MINZ members are currently updating the manual, adding answers to Test Yourself questions and incorporating local Real Enquiries and Answers.

Contribute to the members-only section of the NZHPA webpage - some suggestions: database of Consumer Information leaflets for S29 or unusual items; database of expiry dates of refrigerated items at room temperature; medicines info bulletins.

- Discussion has taken place with Dave Woods regarding possible additions to the website
- An archive of the MI Question of the month has now been incorporated
- Agreement to include a repository of abstracts from NZHPA Conference and any other relevant research

Income and expenditure

Income for the year: \$4,840
Expenditure: \$1,977
Net surplus: \$2,863

Balance in account: \$18,422

Officers and Members

Jocelyn Livesey (convenor), Janice Young (co-convenor), Melissa Young (minutes secretary), Chloe Campbell, Bob Buckham, Chris Jay, Annie Egan, Pam Buffery

Attendance at meetings

Another successful SIG meeting was held in Wellington in conjunction with the CNO SIG. There were 47 attendees and as well as informative presentations by both members and invited speakers, useful discussions took place as to areas the SIG should be trying to progress.

AGM: 25 in attendance

Jocelyn Livesey
Drug Information and Clinical Pharmacy SIG Convenor
July 2010



Compounding, Nutrition and Oncology SIG Annual Report 2010

Introduction

Paula Ferguson elected to Convenor September 2009, Anita Frew elected to Deputy Convenor & Maxine Handford to Secretary May 2010

Achievements against annual plan

A very successful and interesting SIG meeting took place in May in Wellington, organised by the DICP SIG. There was a varied programme covering extemp, aseptic and cyto compounding and nutrition with presentations by CNO SIG members and external people. There were also combined sessions with the DICP SIG as this formula has proved successful in the past.

Developing national compounding standards and standardising formulas was originally discussed within the CNO SIG group but has been superseded by a working party set up by Pharmac at the suggestion of the Telepaeds group. Paula Ferguson is a member of this group and is liaising between the group and CNO SIG. This is the priority for this year.

A position statement on the reconstitution of BCG vaccines for bladder instillations will be published shortly.

Officers and Members

Convenor: Paula Ferguson
Co-convenor: Anita Frew
Secretary: Maxine Handford

Responsibilities: Oncology lead by Anita Frew
Extemp. Compounding lead by Paula Ferguson
Nutrition lead by Doreen Liow
Aseptic Compounding lead by Derryn Gargiulo

Membership for 2009/2010: 40

Attendance at CNO SIG conference - 10-20 at each of the sessions for the May meeting

Attendance at AGM - 10

Paula Ferguson
Compounding, Nutrition and Oncology SIG Convenor
July 2010



Technician SIG Annual Report 2010

Introduction

Our aim this year was to try and raise the profile of the Technicians SIG, encouraging increased membership and attendance at Study days and the NZHPA annual conference. Looking forward we need to review our original objective of holding two study days a year as sponsorship for events like this and support for delegates to attend is becoming increasingly difficult to procure. For 2011 we will endeavour to hold one study day early in the year and encourage attendance at the annual conference as the opportunity to get together later in the year.

Achievements against annual plan

Two successful study days held. One was held in Christchurch in November 2009 with 65 delegates, the other being held in Hastings in May 2010 with 24 delegates. Both were well organised and the programmes were interesting, interactive and enjoyable. Congratulations to Bronwyn, Ros and the team from Christchurch and Brenda, Kelly and the team from Hawke's Bay for all their hard work in putting together such fantastic events – it was well worth it.

Income and expenditure

Received Sponsorship and registration fees for both Study days held this year. Budgets were submitted and approved. Expenditure was only costs for these events as well. Current balance is \$3,864.

Officers and Members

Convenor: Dianne Gulliver
Deputy: Nic Ellinger
Members: Dallas Murie
Carol Robinson
Carole Dawson
Paula Ferguson
Anne Thorne
Brenda Edwards

Dianne Gulliver
Technician SIG Convenor
July 2010



Notes on Injectable Drugs Annual Report 2010

Introduction

Lucy Broughton and her team of editors have completed all the monographs for the 6th Edition. No mean feat considering the brand changes that have taken place since the publication of the 5th Edition. Thank you to Lucy and her team for their tremendous work which takes place in their personal time. The monographs have now been disseminated to a team of proof readers for final checking.

As the proof reading is taking place quotes for printing of the new edition are being sought. At present we are sifting through quotes and attempting to get our heads around printing jargon and paper types to bring the 6th Edition completely up to specification for our end users. Alternative binding options are being considered given the difficulties experienced by some customers with the 5th edition. Solutions may include a departure from the traditional look of the previous editions in order to solve the problem and still function in a user friendly fashion. Watch this space for the new look NoIDs 6th Edition.

Lorraine Welman
On behalf of Lucy Broughton
Chief Editor of NoIDs
July 2010



2010 Report from NZHPA Archivist Euan Galloway

The Presidential Chain, Noel Hall Report and A.P. Codeine

30 years ago at the 1980 NZHPA Conference in Hamilton, Ken Huse Managing Director of Glaxo Laboratories [now GSK] presented the then President of NZHPA Maurice Malone with a silver Presidential Chain of Office. It was reported at the time that the wearing of the Chain "gave a certain dignity to an event"!!



NZHPA President Maurice Malone with
Glaxo Managing Director Ken Huse
NZHPA Conference, Hamilton October 1980

It is some years since I last recall seeing the Presidential Chain worn at an official function – though a paper substitute was offered to the President Billy Allan at the AGM last year. Maybe wearing the Chain at official functions should be a condition of holding office as President of NZHPA?

*** **

40 years ago in 1970 in Britain the Noel Hall Report was published, advising their hospital pharmaceutical service on the best use of pharmacists and support staff; and a suitable career structure for both. This report facilitated implementation in New Zealand of many of the

recommendations of the Berry Report, which two years earlier had come to the same conclusions. An important development in both countries was the introduction of 'ward pharmacy', which later evolved into clinical pharmacy as we know it today. The Noel Hall Report also noted that (in the UK) *the workforce was unequal to the work load*. Is New Zealand much different 40 years later??

*** **

Barbara O'Driscoll recently passed onto me for inclusion in the NZHPA archives, her records of her long time on the Executive and as President [1996 and 97]. Thank you Barbara. Amongst them were some early records of Palmerston North Hospital Pharmacy and a tape recording of reminiscences by Doug Warr – Chief Pharmacist Palmerston North Hospital 1961-1982, NZHPA Executive 1963-1978 and President 1972-75. An interesting one was the Phenacetin Story "..... which began in about 1963 with a patient – a young mother with two small children and a history of chronic ingestion of large numbers of A.P.Codeine tablets BP [aspirin 250mg, phenacetin 250mg and codeine phos 8mg]. This had occurred over a number of years for a pain that probably had a strong psychosomatic element. Her diagnosis was renal capillary necrosis or "phenacetin kidney" and her prognosis was poor. This was before renal dialysis, and her life came to a premature end.

"On behalf of her consultant I searched the literature about the effects and side-effects of phenacetin. It was a grim and disquieting picture, and I questioned what were we doing in Palmerston North Hospital handing out upwards of 100,000 tablets each year of a potentially hazardous substance and, in effect, encouraging their use? There appeared to be no reason why the phenacetin in the tablet should not be replaced by its active metabolite paracetamol which has a much better safety record. Eventually I compiled a paper on the subject recommending that we introduce A.P.Codeine tablets made to this revised formula. I sent it to the Medical Superintendent who was impressed but said I had to gain the approval of the Consultants' Committee before anything could be done.

"This led to another schism, with some strong supporters and some equally vehement opponents. Eventually we arrived at a compromise. We would introduce our new tablets, to be called A.P.Codeine PNH while retaining stocks of the old formula for patients of the opposing doctors. [Later Doug confessed that he did nothing of the kind. Everybody got the new formula and he kept his fingers crossed.]

"We got K.P.s [Kempthorne Prosser pharmaceutical manufacturing factory in Dunedin] to make our first batch of 100,000 tablets. I never could understand why the codeine content of A.P.Codeine tablets should be fixed at 8mg, so when I placed the order I made it 10mg – much tidier. What I didn't realise was that this placed the tablets in a different category in the Poisons Act [now the Misuse of Drugs] where controls were more rigid. Fortunately nobody ever tumbled to it. K.P.s had some difficulty in making the tablets, but eventually they arrived.

"From the outset they were a great success. Maybe the extra 2mg of codeine made a difference but it came to be accepted that the hospital A.P.Codeine PNH were more effective than the ordinary kind. GPs sent patients to us to secure supplies so I got local pharmacies to hold stocks to meet the demand. We needed new stocks earlier than expected and K.P.s had had so much difficulty in preparing the first batch they were not interested in a second order. So I got Burrows Wellcome to make them. Later they put their own version on the market as CODCOMOL [aspirin 250mg, paracetamol 250mg and codeine phos 8mg] and we duly switched to them.

"The point of this story is that Palmerston North was among the first hospitals in the world, and certainly the first in Australasia, to make this change in A.P.Codeine. I read a paper on it at our 1964 NZHPA Conference in Whangarei, and offered to supply other hospitals with stocks but only one, Hastings, ever took the advantage of the offer. In due course the use of phenacetin was banned anyway."

*** **

The archives of NZHPA are a repository of hospital pharmacy information and memorabilia, but the collection needs to be ongoing. I am always interested in photographs, records, copies of conference papers and any other memorabilia of hospital pharmacy practice members may have, or happen to find. Please also send me anything you have that describes the current activities and significant events of your pharmacy.

Anne Flynn retires this month after almost 35 years as Chief Pharmacist at Timaru Hospital – now Anne, you must have a lot of memories to record and memorabilia to pass on!

**Please help save our historical documents
and create a record of our present activities for the future.**

Euan Galloway
B.Pharm FPS FHPA MNZCP ED

PO Box 11-640, Manners Street, Wellington 6142
Phone: 04 802 0032
E-mail: e.galloway@psnz.org.nz

July 2010